t
Novacyt S.A. announced on 1 September 2026 that it has entered into a Master Collaboration Agreement (MCA) with Illumina. This Agreement has an initial five-year term and establishes a framework for the parties to explore potential future collaboration. Under the MCA, Novacyt will provide expertise complementary to Illumina.
| Date | 1 Sept 2026 |
| Time | 07:00:14 |
| Category | Acquisitions and alliances |
| ID | 7706S |
Novacyt S.A.
("Novacyt", the "Company" or the "Group")
Master Collaboration Agreement with Illumina
Agreement supports evaluation of future collaboration and product development opportunities
Paris, France, and Manchester, UK - 1 September 2026 - Novacyt S.A. (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international molecular diagnostics company with a broad portfolio of integrated technologies and services, announces that it has entered into a Master Collaboration Agreement ("MCA" or "Agreement") with Illumina (NASDAQ: ILMN) a global leader in DNA sequencing and array-based technologies, for an initial five-year term.
The Agreement establishes a framework under which the parties may explore potential future collaboration in areas of mutual interest, subject to separate written project agreements. Novacyt will provide expertise complementary to Illumina, to allow exploration of deeper product development and commercial collaboration. Novacyt looks forward to providing updates on any material developments arising from the relationship as appropriate.
Lyn Rees, Chief Executive Officer, said: "The MCA establishes a strategic framework to facilitate knowledge sharing and training between Novacyt and Illumina and the potential to explore future collaboration, reflecting the value of Novacyt's product development capabilities."
This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014.
Contacts
|
Novacyt SA |
||||
|
Lyn Rees, Chief Executive Officer |
Via Walbrook PR |
|||
|
Steve Gibson, Chief Financial Officer
|
|
|||
|
|
|
|||
|
SP Angel Corporate Finance LLP (Nominated Adviser and Broker) |
+44 (0)20 3470 0470 |
|||
|
Matthew Johnson / Charlie Bouverat (Corporate Finance) Vadim Alexandre / Rob Rees (Corporate Broking) |
|
|||
|
|
|
|||
|
Singer Capital Markets (Joint Broker) |
+44 (0) 20 7496 3000 |
|||
|
Russell Cook / Graham Hertrich / James Fischer |
|
|||
|
|
|
|||
|
Allegra Finance (French Listing Sponsor) Rémi Durgetto / Yannick Petit |
+33 (1) 42 22 10 10 |
|||
|
|
|
|||
|
Walbrook PR (Financial PR & IR) Paul McManus / Alice Woodings / William Turner |
+44 (0)20 7933 8780 or [email protected] +44 (0)7980 541 893 / +44 (0)7407 804 654 / +44 (0)7407 020 470 |
|||
About Novacyt Group (www.novacyt.com)
Novacyt is an international molecular diagnostics company providing a broad portfolio of integrated technologies and services, primarily focused on the delivery of genomic medicine. The Company develops, manufactures, and commercialises a range of molecular assays and instrumentation to deliver workflows and services that enable seamless end-to-end solutions from sample to result across multiple sectors including human health, animal health and environmental.
The Company is divided into three business segments:
|
Clinical |
Broad portfolio of human clinical in vitro diagnostic products, workflows and services focused on three therapeutic areas: · Reproductive Health: NIPT, Cystic Fibrosis and other rapid aneuploidy tests · Precision Medicine: DPYD genotyping assay · Infectious Diseases: Winterplex, multiplex winter respiratory PCR panel
|
|
Instrumentation |
Portfolio of next generation size selection DNA sample preparation platforms and rapid PCR machines, including: · Ranger® Technology: automated DNA sample preparation and target enrichment technology · genesig q16 and q32 real-time quantitative PCR (qPCR) instruments
|
|
Research Use Only |
Range of services for the life sciences industry: · Design, manufacture, and supply of high-performance qPCR assays and workflows for use in human health, agriculture, veterinary and environmental, to support global health organisations and the research industry · Pharmaceutical research services: whole genome sequencing (WGS) / whole exome sequencing (WES) |
Novacyt is headquartered in Le Vésinet in France with offices in the UK (Manchester), Singapore, the US and Canada and has a commercial presence in over 65 countries, including Australia, following the recent acquisition of Southern Cross Diagnostics in March 2026, which has opened new distribution channels to the life sciences and diagnostics industries in the territory and the wider Asia-Pacific region.
The Company is listed on the London Stock Exchange's AIM market ("NCYT") and on the Paris Stock Exchange Euronext Growth ("ALNOV").
For more information, please refer to the website: www.novacyt.com